Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ivan Gonzalez

Thoracic Surgery (Cardiothoracic Vascular Surgery) San Juan, PR Medical Doctor

NPI 1720084171 CMS profile 32476

Ave Americo Miranda, Num 401, San Juan, PR 00927

Open in the dashboard

General payments

$19,675

174 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ivan Gonzalez of San Juan, PR is reported in the CMS Open Payments database as having received $19,675 across 174 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $447 21
2024 General $189 17
2023 General $510 12
2022 General $12,239 15
2021 General $2,234 37
2020 General $942 25
2019 General $3,114 47

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ivan Gonzalez
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Ivan Gonzalez were reported at $447. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Ivan Gonzalez Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $3,114 $886 $178–$3,167 $163
2020 $942 $341 $108–$1,605 $114
2021 $2,234 $453 $125–$1,886 $132
2022 $12,239 $695 $180–$2,566 $149
2023 $510 $745 $205–$2,662 $160
2024 $189 $799 $214–$2,967 $164
2025 $447 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $12,344 31 payments
  2. Edwards Lifesciences Corporation $4,157 89 payments
  3. Medtronic, Inc. $1,236 16 payments
  4. Medtronic Vascular, Inc. $798 25 payments
  5. LivaNova USA, Inc. $491 4 payments
  6. E.R. Squibb & Sons, L.L.C. $238 1 payment
  7. Atricure, Inc. $155 1 payment
  8. Bard Peripheral Vascular, Inc. $124 1 payment
  9. Abiomed $30 1 payment
  10. Biotronik Inc. $24 1 payment
  11. Other $79 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $12,910 11 payments
  2. Food and Beverage $6,527 162 payments
  3. Consulting Fee $238 1 payment
Products named General payments · program years 2019–2025
  1. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $11,134 2 payments
  2. EDWARDS INTUITY Elite valve system $1,495 9 payments
  3. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $775 14 payments
  4. Edwards SAPIEN 3 Transcatheter Heart Valve $724 19 payments
  5. CoreValve Evolut Transcatheter Valve Systems $687 18 payments
  6. Micra $462 3 payments
  7. CoreValve Evolut Transcatheter Valve Systems $368 6 payments
  8. HeartMate 3 Left Ventricular Dev $270 4 payments
  9. HemoSphere $269 5 payments
  10. PORTICO $259 8 payments
  11. Other $2,794 51 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

49

Median for Cardiac Surgery: 68

Drug cost

$492

Median for Cardiac Surgery: $445

Branded share of claims

0%

Median for Cardiac Surgery: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mupirocin Generic 37 $364
Gabapentin Generic 12 $128

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 411 Part D prescribers listed as Cardiac Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$5,670

Medicare's payments for the services billed

Medicare patients

23

Average age 77

Services billed

30

12 women, 11 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Diabetes 74%
Alzheimer's or dementia 61%
Chronic kidney disease 52%
Heart failure 48%
Arthritis 48%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

174 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record